-
Something wrong with this record ?
Perinucleolar heterochromatin during the cell differentiation using human leukemic neutrophils as a convenient model
Karel Smetana, Hana Klamová, Ilona Jirásková, Dana Mikulenková
Language English Country Czech Republic
Document type Research Support, Non-U.S. Gov't
- MeSH
- Benzamides therapeutic use MeSH
- Cell Differentiation * genetics immunology drug effects MeSH
- Cell Nucleus * genetics microbiology pathology MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy genetics immunology MeSH
- Heterochromatin * genetics immunology pathology MeSH
- Bone Marrow immunology drug effects MeSH
- Humans MeSH
- Models, Genetic MeSH
- Neutrophils immunology pathology drug effects MeSH
- Piperazines therapeutic use MeSH
- Granulocyte Precursor Cells immunology pathology drug effects MeSH
- Pyrimidines therapeutic use MeSH
- Statistics as Topic MeSH
- Cell Nucleus Structures genetics immunology microbiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
The perinucleolar region represents a special nuclear compartment involved in the cell malignancy and the perinucleolar heterochromatin reflects the presence of silent genes. The present study was undertaken to provide complementary and missing information on the perinucleolar heterochromatin in differentiating neutrophils in the bone marrow of patients with the chronic myeloid leukemia. That lineage is a very convenient model because of the increased number of granulocytic precursors that is satisfactory for size as well as optical density measurements in single cells. Moreover, the differentiation stages of neutrophils are well defined and easily identified. According to diameter measurements the enlarged width of the perinucleolar heterochromatin shell accompanied the decreasing nucleolar size in advanced stages of the cell differentiation. Such trend was not influenced by the anti-leukemic therapy with imatinib. Thus the increasing size of the perinucleolar heterochromatin shell with silent genes might reflect the genomic stability of the perinucleolar region during the cell differentiation. On the other hand, the increased perinucleolar heterochromatin condensation after the specific anti-leukemic therapy with imatinib indicated a “premature terminal differentiation” of leukemic neutrophils.
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15030071
- 003
- CZ-PrNML
- 005
- 20160129105259.0
- 007
- ta
- 008
- 150922s2015 xr a f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jab.2015.03.001 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Smetana, Karel, $d 1958- $7 jn20000710554 $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 245 10
- $a Perinucleolar heterochromatin during the cell differentiation using human leukemic neutrophils as a convenient model / $c Karel Smetana, Hana Klamová, Ilona Jirásková, Dana Mikulenková
- 504 __
- $a Literatura
- 520 9_
- $a The perinucleolar region represents a special nuclear compartment involved in the cell malignancy and the perinucleolar heterochromatin reflects the presence of silent genes. The present study was undertaken to provide complementary and missing information on the perinucleolar heterochromatin in differentiating neutrophils in the bone marrow of patients with the chronic myeloid leukemia. That lineage is a very convenient model because of the increased number of granulocytic precursors that is satisfactory for size as well as optical density measurements in single cells. Moreover, the differentiation stages of neutrophils are well defined and easily identified. According to diameter measurements the enlarged width of the perinucleolar heterochromatin shell accompanied the decreasing nucleolar size in advanced stages of the cell differentiation. Such trend was not influenced by the anti-leukemic therapy with imatinib. Thus the increasing size of the perinucleolar heterochromatin shell with silent genes might reflect the genomic stability of the perinucleolar region during the cell differentiation. On the other hand, the increased perinucleolar heterochromatin condensation after the specific anti-leukemic therapy with imatinib indicated a “premature terminal differentiation” of leukemic neutrophils.
- 650 12
- $a buněčné jádro $x genetika $x mikrobiologie $x patologie $7 D002467
- 650 _2
- $a struktury buněčného jádra $x genetika $x imunologie $x mikrobiologie $7 D022003
- 650 12
- $a buněčná diferenciace $x genetika $x imunologie $x účinky léků $7 D002454
- 650 12
- $a heterochromatin $x genetika $x imunologie $x patologie $7 D006570
- 650 _2
- $a neutrofily $x imunologie $x patologie $x účinky léků $7 D009504
- 650 _2
- $a chronická myeloidní leukemie $x farmakoterapie $x genetika $x imunologie $7 D015464
- 650 _2
- $a benzamidy $x terapeutické užití $7 D001549
- 650 _2
- $a piperaziny $x terapeutické užití $7 D010879
- 650 _2
- $a pyrimidiny $x terapeutické užití $7 D011743
- 650 _2
- $a modely genetické $7 D008957
- 650 _2
- $a kostní dřeň $x imunologie $x účinky léků $7 D001853
- 650 _2
- $a prekurzorové buňky granulocytů $x imunologie $x patologie $x účinky léků $7 D042381
- 650 _2
- $a statistika jako téma $7 D013223
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Klamová, Hana $7 xx0081721 $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Jirásková, Ilona $7 xx0102284 $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Mikulenková, Dana $7 xx0182877 $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 773 0_
- $t Journal of applied biomedicine $x 1214-021X $g Roč. 13, č. 3 (2015), s. 225-232 $w MED00012667
- 856 41
- $u https://jab.zsf.jcu.cz/pdfs/jab/2015/03/07.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y 4 $z 0
- 990 __
- $a 20150522215938 $b ABA008
- 991 __
- $a 20160129105419 $b ABA008
- 999 __
- $a ok $b bmc $g 1091014 $s 913166
- BAS __
- $a 3
- BMC __
- $a 2015 $b 13 $c 3 $d 225-232 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
- LZP __
- $c NLK184 $d 20160129 $a NLK 2015-40/dk